AMDL CEO Gary Dreher Interviewed by World Talk Radio on Status of China Acquisitions
March 23 2006 - 4:20PM
PR Newswire (US)
TUSTIN, Calif., March 23 /PRNewswire-FirstCall/ -- AMDL, Inc.
(AMEX:ADL), developer and marketer of tests for the early detection
of cancer and other serious diseases, today announced that its CEO,
Gary L. Dreher, was interviewed by Francis Gaskins at World Talk
Radio about the Company's strategy in purchasing two pharmaceutical
companies in China, the status of its DR-70(R) proprietary test for
cancer, and the development of its Combination Immune Therapy for
the treatment of cancer. The interview can be heard at
http://www.worldtalkradio.com/archive.asp?aid=6452 . Mr. Dreher
explains in the interview that the move into China will globalize
the Company and give AMDL a "vast opportunity" to market its cancer
screening test and its gene therapy treatment there. AMDL's CEO
said the ongoing due diligence is going well and nearing a
conclusion. About AMDL AMDL, Inc. (AMEX:ADL), headquartered in
Tustin, California, is a theranostics company, involved in the
detection and treatment of the same disease, cancer. AMDL is the
inventor, developer and worldwide marketer through exclusive
distribution agreements of the DR-70(R) non-invasive cancer blood
test, which has demonstrated its ability to detect the presence in
humans of up to 13 cancers 84 percent of the time overall. In a
study published in the Journal of Immunoassay (1998, vol. 19, pp
63-72) DR-70(R) was shown to detect at least 13 different types of
cancer (lung, breast, stomach, liver, colon, rectal, ovarian,
esophageal, cervical, trophoblastic, thyroid, malignant lymphoma,
pancreatic) although the sample size for 9 of the cancers was not
statistically significant. Clinical trials of DR-70(R) have been
conducted in Canada, China, Germany, Taiwan and Turkey. DR-70(R)
can detect many kinds of cancer using a single tube of blood,
eliminating the need for costly, multiple tests. AMDL also owns a
combination immunogene therapy technology that is a possible
treatment for those already diagnosed with cancer and could
eventually be used as a vaccine to protect patients known to be at
risk because of a family history for certain types of cancer. The
combination therapy both builds the body's immune system and
destroys cancer cells. More information about AMDL and its
additional products can be obtained at http://www.amdl.com/.
Forward-Looking Statements We intend that the statements in this
press release that are not historical constitute "forward-looking
statements" within the meaning of Section 27A of the Securities Act
of 1933, as amended and Section 21 of the Securities Exchange Act
of 1934, as amended and are subject to numerous risks and
uncertainties, including the risks (i) that the transaction
described may not be completed when expected, or at all, (ii) the
risk that the terms of the definitive acquisition agreements may
materially differ from that disclosed herein, (iii) the risks
related to the inability to obtain or meet conditions imposed for,
governmental and other approvals of the transaction, including the
approval by the stockholders of AMDL, (iv) risks related to the
uncertainty surrounding the transaction and transactions of this
type and (v) the costs related thereto. In addition, these
forward-looking statements are subject to the other risks of AMDL's
business, including, but not limited to, (a) AMDL's failure to
complete successfully the development of new or enhanced products,
(b) AMDL's future capital needs, (c) the lack of market demand for
any new or enhanced products that AMDL may develop, (d) the lack of
market acceptance of AMDL's products and its limited revenues to
date, (e) the success of competitive products, other economic
factors affecting AMDL and its markets, and (f) other risks
detailed from time to time in the Company's filings with the
Securities and Exchange Commission. The actual results may differ
materially from those contained in this press release. The Company
disclaims any obligation to update any statements in this press
release in the event of new circumstances or unanticipated events
that may occur in the future. Contact: AMDL, Inc. Gary L. Dreher
President & CEO (714) 505-4460 DATASOURCE: AMDL, Inc. CONTACT:
Gary L. Dreher, President & CEO of AMDL, Inc., +1-714-505-4460
Web site: http://www.amdl.com/
http://www.worldtalkradio.com/archive.asp?aid=6452
Copyright
Amdl (AMEX:ADL)
Historical Stock Chart
From May 2024 to Jun 2024
Amdl (AMEX:ADL)
Historical Stock Chart
From Jun 2023 to Jun 2024